Here are three things to know:
1. The IMblaze370 phase 3 trial included more than 360 metastatic CRC patients for whom at least two prior chemotherapy regimens had failed.
2. The majority of participants — 90 percent — had tumors characterized by microsatellite stability; tumors with microsatellite instability have been shown to respond to immunotherapy.
3. There was no significant difference in progression-free survival between the treatments.
More articles on gastroenterology:
$5k colonoscopy? Contract dispute in Mississippi could mean patients foot the bill
Pentax Medical posts lecture series on endoscopic infection control — 6 insights
